Todd M. Bauer
About
Todd M. Bauer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Todd M. Bauer has authored 264 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 188 papers in Oncology, 132 papers in Pulmonary and Respiratory Medicine and 81 papers in Molecular Biology. Recurrent topics in Todd M. Bauer's work include Lung Cancer Treatments and Mutations (77 papers), Cancer Immunotherapy and Biomarkers (53 papers) and Lung Cancer Research Studies (34 papers). Todd M. Bauer is often cited by papers focused on Lung Cancer Treatments and Mutations (77 papers), Cancer Immunotherapy and Biomarkers (53 papers) and Lung Cancer Research Studies (34 papers). Todd M. Bauer collaborates with scholars based in United States, France and Italy. Todd M. Bauer's co-authors include Alice T. Shaw, Benjamin Solomon, Enriqueta Felip, Holger Thurm, Manish R. Patel, Gerson Peltz, Benjamin Besse, Antonello Abbattista, Jeffrey R. Infante and Jill S. Clancy and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Todd M. Bauer
251 papers receiving 8.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Todd M. Bauer United States | 50 | 5.4k | 4.2k | 2.9k | 1.5k | 1.4k | 264 | 8.6k | ||
| Leena Gandhi United States | 46 | 5.8k 1.1× | 4.1k 1.0× | 2.7k 0.9× | 1.3k 0.8× | 1.8k 1.3× | 145 | 8.6k | ||
| Melissa L. Johnson United States | 42 | 5.0k 0.9× | 3.4k 0.8× | 2.3k 0.8× | 1.1k 0.7× | 1.2k 0.8× | 359 | 7.1k | ||
| Marcin Kowanetz United States | 45 | 9.3k 1.7× | 5.7k 1.4× | 2.9k 1.0× | 1.8k 1.2× | 2.6k 1.8× | 109 | 12.3k | ||
| Binghe Xu China | 41 | 6.1k 1.1× | 2.8k 0.7× | 3.2k 1.1× | 3.0k 1.9× | 808 0.6× | 387 | 9.1k | ||
| Jamie E. Chaft United States | 43 | 7.0k 1.3× | 6.4k 1.5× | 1.9k 0.7× | 1.5k 1.0× | 1.0k 0.7× | 175 | 10.2k | ||
| Caicun Zhou China | 39 | 6.4k 1.2× | 6.8k 1.6× | 2.6k 0.9× | 1.6k 1.1× | 601 0.4× | 136 | 8.9k | ||
| Shumei Kato United States | 38 | 4.5k 0.8× | 2.4k 0.6× | 2.2k 0.7× | 2.6k 1.7× | 1.3k 0.9× | 174 | 7.5k | ||
| Theodore F. Logan United States | 37 | 4.5k 0.8× | 3.2k 0.8× | 3.3k 1.1× | 1.5k 1.0× | 2.1k 1.5× | 120 | 8.0k | ||
| Petri Bono Finland | 44 | 3.9k 0.7× | 2.4k 0.6× | 2.7k 0.9× | 1.6k 1.0× | 1.3k 0.9× | 156 | 7.5k | ||
| Rafał Dziadziuszko Poland | 44 | 5.8k 1.1× | 6.3k 1.5× | 2.7k 0.9× | 1.8k 1.2× | 467 0.3× | 290 | 9.0k |
Countries citing papers authored by Todd M. Bauer
Since
Specialization
Citations
This map shows the geographic impact of Todd M. Bauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd M. Bauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd M. Bauer more than expected).
Fields of papers citing papers by Todd M. Bauer
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Todd M. Bauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd M. Bauer. The network helps show where Todd M. Bauer may publish in the future.
Co-authorship network of co-authors of Todd M. Bauer
This figure shows the co-authorship network connecting the top 25 collaborators of Todd M. Bauer. A scholar is included among the top collaborators of Todd M. Bauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd M. Bauer. Todd M. Bauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Strowd, Roy E., Macarena de la Fuente, Todd M. Bauer, et al.. (2025). Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: results of the glioblastoma expansion cohort. Neuro-Oncology Advances.
2.
Naing, Aung, Amit Mahipal, Milind Javle, et al.. (2025). Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study. PubMed. 8(1). 71–81.
3.
Maio, Michele, Víctor Moreno, Juan Martín-Liberal, et al.. (2025). First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 13(8). e011475–e011475.
4.
Solomon, Benjamin, Geoffrey Liu, Enriqueta Felip, et al.. (2024). Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. Journal of Clinical Oncology. 42(29). 3400–3409.
5.
LoRusso, Patricia, Noboru Yamamoto, Manish R. Patel, et al.. (2023). The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study. Cancer Discovery. 13(8). 1802–1813.
6.
Hamilton, Erika, Judy S. Wang, Amit M. Oza, et al.. (2023). First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma. Molecular Cancer Therapeutics. 22(10). 1154–1165.
7.
Bauer, Todd M., Kathleen N. Moore, Janet S. Rader, et al.. (2023). A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Targeted Oncology. 18(4). 517–530.
8.
Hamid, Omid, Jessica C. Hassel, Alexander N. Shoushtari, et al.. (2023). Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. Journal for ImmunoTherapy of Cancer. 11(6). e006747–e006747.
9.
Goldman, Jonathan W., Sarina A. Piha‐Paul, Brendan D. Curti, et al.. (2022). Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 28(17). 3709–3719.
10.
Davar, Diwakar, Roberta Zappasodi, Hong Wang, et al.. (2022). Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research. 28(18). 3990–4002.
11.
Lim, Emerson A., Johanna C. Bendell, Gerald S. Falchook, et al.. (2022). Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clinical Cancer Research. 28(22). 4871–4884.
12.
Camidge, D. Ross, Daniel Morgensztern, Rebecca S. Heist, et al.. (2021). Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma. Clinical Cancer Research. 27(21). 5781–5792.
13.
Drake, Charles G., Russell K. Pachynski, Sumit K. Subudhi, et al.. (2021). Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 25(2). 219–228.
14.
Saleh, Mansoor N., Manish R. Patel, Todd M. Bauer, et al.. (2021). Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clinical Cancer Research. 27(19). 5236–5247.
15.
Shaw, Alice T., Todd M. Bauer, Filippo de Marinis, et al.. (2020). First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer. New England Journal of Medicine. 383(21). 2018–2029.
16.
Harding, James J., Andrew X. Zhu, Todd M. Bauer, et al.. (2019). A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical Cancer Research. 25(17). 5202–5211.
17.
Abramson, Vandana G., Mafalda Oliveira, Andrés Cervantes, et al.. (2019). A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. Breast Cancer Research and Treatment. 178(1). 121–133.
18.
Bendell, Johanna C., Anna M. Varghese, David M. Hyman, et al.. (2018). A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clinical Cancer Research. 24(14). 3253–3262.
19.
Strickler, John H., Colin D. Weekes, John Nemunaitis, et al.. (2018). First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 36(33). 3298–3306.
20.
Infante, Jeffrey R., Antoine Hollebecque, Sophie Postel‐Vinay, et al.. (2016). Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. Clinical Cancer Research. 23(10). 2423–2432.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Leena Gandhi Breakdown of academic impact, for papers by Melissa L. Johnson Breakdown of academic impact, for papers by Marcin Kowanetz Breakdown of academic impact, for papers by Binghe Xu Breakdown of academic impact, for papers by Jamie E. Chaft Breakdown of academic impact, for papers by Caicun Zhou Breakdown of academic impact, for papers by Shumei Kato Breakdown of academic impact, for papers by Theodore F. Logan Breakdown of academic impact, for papers by Petri Bono Breakdown of academic impact, for papers by Rafał Dziadziuszko